JP2014517750A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517750A5
JP2014517750A5 JP2014510302A JP2014510302A JP2014517750A5 JP 2014517750 A5 JP2014517750 A5 JP 2014517750A5 JP 2014510302 A JP2014510302 A JP 2014510302A JP 2014510302 A JP2014510302 A JP 2014510302A JP 2014517750 A5 JP2014517750 A5 JP 2014517750A5
Authority
JP
Japan
Prior art keywords
supar
support
cartridge
housing
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014510302A
Other languages
English (en)
Japanese (ja)
Other versions
JP6055464B2 (ja
JP2014517750A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/000240 external-priority patent/WO2012154218A2/en
Publication of JP2014517750A publication Critical patent/JP2014517750A/ja
Publication of JP2014517750A5 publication Critical patent/JP2014517750A5/ja
Application granted granted Critical
Publication of JP6055464B2 publication Critical patent/JP6055464B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014510302A 2011-05-09 2012-05-09 循環血中の可溶性ウロキナーゼ受容体の低減 Active JP6055464B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161457665P 2011-05-09 2011-05-09
US61/457,665 2011-05-09
PCT/US2012/000240 WO2012154218A2 (en) 2011-05-09 2012-05-09 Reducing soluble urokinase receptor in the circulation

Publications (3)

Publication Number Publication Date
JP2014517750A JP2014517750A (ja) 2014-07-24
JP2014517750A5 true JP2014517750A5 (cg-RX-API-DMAC7.html) 2015-06-11
JP6055464B2 JP6055464B2 (ja) 2016-12-27

Family

ID=47139854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014510302A Active JP6055464B2 (ja) 2011-05-09 2012-05-09 循環血中の可溶性ウロキナーゼ受容体の低減

Country Status (5)

Country Link
US (1) US9867923B2 (cg-RX-API-DMAC7.html)
EP (1) EP2707055B1 (cg-RX-API-DMAC7.html)
JP (1) JP6055464B2 (cg-RX-API-DMAC7.html)
ES (1) ES2765006T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012154218A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2608804A4 (en) * 2010-08-27 2015-03-11 Univ Miami TREATMENT OF KIDNEY DISEASES
WO2012154218A2 (en) 2011-05-09 2012-11-15 The University Of Miami Reducing soluble urokinase receptor in the circulation
JP6438474B2 (ja) * 2013-08-01 2018-12-12 ザ ジェネラル ホスピタル コーポレイション 非グリコシル化suPARバイオマーカー及びその使用
CN103933615B (zh) * 2014-04-08 2015-10-28 华南理工大学 一种用于肾小球滤过膜修复的自组装多孔聚合物膜及其制备方法与应用
WO2017040488A1 (en) * 2015-08-31 2017-03-09 Rush University Medical Center Prediction of kidney disease, severity and related treatment approaches
WO2017053976A1 (en) * 2015-09-25 2017-03-30 The General Hospital Corporation DIAGNOSTIC ASSAYS FOR SUPAR-β3 INTEGRIN DRIVEN KIDNEY DISEASES
EP3735281B1 (en) 2018-01-05 2024-11-27 Path Ex, Inc. Device for the capture and removal of disease material from fluids
JP2022513317A (ja) * 2018-09-28 2022-02-07 ヨッヘン ライザー suPARならびに急性腎傷害の予測および治療
US20230348613A1 (en) * 2020-06-05 2023-11-02 The Regents Of The University Of California Methods and antibodies in treatment of focal segmental glomerulosclerosis (fsgs)
WO2022125776A2 (en) 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases
JP7553105B2 (ja) * 2021-03-04 2024-09-18 学校法人産業医科大学 巣状分節性糸球体硬化症の発症時期を推定する方法
TWI830166B (zh) 2022-03-08 2024-01-21 國立成功大學 病理切片影像的脂滴分割方法與電腦程式產品
JP2024034246A (ja) * 2022-08-31 2024-03-13 国立大学法人群馬大学 特発性ネフローゼ症候群の検査方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US6794358B1 (en) 1997-03-28 2004-09-21 Brigham And Women's Hospital Peptide ligands of the urokinase receptor
US6774102B1 (en) 1999-09-29 2004-08-10 Gambro Dialysatoren Gmbh & Co. Kg Extracorporeal endotoxin removal method
SE0201257D0 (sv) * 2002-04-25 2002-04-25 Medical Invest In Sweden Ab Improved Separation
US7138230B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US7560244B2 (en) 2003-06-04 2009-07-14 Joslin Diabetes Center, Inc. Method of evaluating a subject for risk or predisposition of reduced renal function over time
AU2005240082B2 (en) * 2004-04-30 2009-07-23 Innatus Corporation Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients
PL1765397T3 (pl) 2004-05-25 2013-04-30 Tactic Pharma Llc Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR)
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20070244046A1 (en) 2006-03-29 2007-10-18 Margarita Gutova Identification and characterization of cancer stem cells and methods of use
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US8815519B2 (en) 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
JP2011503531A (ja) 2007-10-26 2011-01-27 ジェネンテック, インコーポレイテッド ウロキナーゼ型プラスミノーゲン活性化因子(uPA)活性の阻害
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
US20110212083A1 (en) 2008-11-06 2011-09-01 University Of Miami Office Of Technology Transfer Role of soluble upar in the pathogenesis of proteinuric kidney disease
WO2012154218A2 (en) 2011-05-09 2012-11-15 The University Of Miami Reducing soluble urokinase receptor in the circulation

Similar Documents

Publication Publication Date Title
Koch et al. Lectin affinity plasmapheresis for middle east respiratory syndrome-coronavirus and Marburg virus glycoprotein elimination
Silliman et al. Experimental prestorage filtration removes antibodies and decreases lipids in RBC supernatants mitigating TRALI in vivo
Sanchez et al. The selective therapeutic apheresis procedures
Aucella et al. Adsorption dialysis: from physical principles to clinical applications
CN102549439B (zh) 用于吸附铁调素的吸附剂
JP2014500735A5 (cg-RX-API-DMAC7.html)
US4512763A (en) Method and apparatus for selective removal of constituents of blood
CN104725506A (zh) 一种应用免疫亲和柱纯化人血清前白蛋白多克隆抗体的方法
US20180093032A1 (en) Targeted apheresis using binding agents or ligands immobilized on membranes
KR102572488B1 (ko) 활성화 백혈구-활성화 혈소판 복합체의 제거 재료
KR20200051578A (ko) 면역 억제성 백혈구 흡착 재료 및 흡착 칼럼
Gong et al. More selective removal of myeloperoxidase‐anti‐neutrophil cytoplasmic antibody from the circulation of patients with vasculitides using a novel double‐filtration plasmapheresis therapy
Lysaght et al. Closed-loop plasmapheresis
Tonev et al. Therapeutic plasma exchange in certain immune-mediated neurological disorders: focus on a novel nanomembrane-based technology
Milly et al. Selenium in renal failure patients
JP2013504751A5 (cg-RX-API-DMAC7.html)
CN103611504A (zh) 一种用于血液灌流去除类风湿因子的吸附材料及其制备方法
Aljadi et al. Activation of basophils is a new and sensitive marker of biocompatibility in hemodialysis
JP6621414B2 (ja) 濾過装置
Tariket et al. Modeling the effect of platelet concentrate supernatants on endothelial cells: focus on endocan/ESM‐1
Sakai Polymethylmethacrylate membrane with a series of serendipity
Xing Effect of different dialysis methods on cellular immunity function of maintenance haemodialysis patients
JP2010530360A (ja) 全身性エリテマトーデスを治療するペプチドおよび全身性エリテマトーデスの治療方法
CN103833843A (zh) 一种从正常人血浆中提取纯化前白蛋白pa的方法
JP5250288B2 (ja) 体液浄化システムの作動方法